

# HEP C = TEST. TREAT. CURE.

## Accessing the inaccessible: An innovative approach to Hepatitis C testing and treatment in the community


Abstract Author: Hansford L<sup>1</sup>

<sup>1</sup> Inclusion, Midlands Partnership NHS Foundation Trust



Hep C is a liver disease

It is transmitted by direct blood to blood contact



Many people living with Hep C have no symptoms



It is estimated that 169,000 people have the virus in England




Risk factors are injecting drug use, unsafe sex, unsafe medical procedures and mother-to-baby




### BEFORE

**Proactive testing**




**Low engagement and treatment due to barriers**


**Hospital-based model**



Numerous GP Appointments prior to hepatology outpatient referral




**Cost of travel**




### NEW PROCESS


**Objective No. 1**  
To extend existing partnership with UHS to offer full treatment on site at Inclusion Andover.





**Objective No. 2**  
Actively targeting those at risk of HCV




**Objective No. 3**  
Supporting and encouraging those with a diagnosis into specialist treatment.



**Peer to peer education and support combined with specialist outreach clinics**





**Hepatologist facilitates clinics in our service**




### OUTCOMES

From July 2017 to Aug 2019




176

176 people tested since the start of the project




x 50

50 different people have been seen at our on-site clinic




x 41

41 PCR+




8 spontaneously cleared  
5 awaiting confirmation of spontaneously cleared




x 23

23 service users treated




x 8

8 currently on treatment




1 Sep

1 due to start in September



x 1

1 left to engage



Our evidence shows BBV Champions have helped to engage the 'hard-to-engage'

Disclosure of Interest Statement: This project was started with a Gilead UK Fellowship Grant